{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-019315","form_type":"8-K","ticker":"MAIA","cik":"0001878313","company_name":"MAIA Biotechnology, Inc.","filed_at":"2025-10-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.952132+00:00","generated_at":"2026-05-17T02:22:21.715504+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"low","headline":"MAIA presents THIO-101 Phase 2 poster at AACR-NCI-EORTC conference on Oct 24, 2025","bullets":["Poster on Ateganosine (THIO) + ICI in advanced NSCLC patients resistant to prior ICI and chemotherapy.","Presented at AACR-NCI-EORTC Molecular Targets Conference in Boston.","No specific efficacy or safety data disclosed in the 8-K filing.","Company provided forward-looking statements caution."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-019315","json":"https://secwatch.observer/filing/0001493152-25-019315.json","markdown":"https://secwatch.observer/filing/0001493152-25-019315.md","text":"https://secwatch.observer/filing/0001493152-25-019315.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1878313/000149315225019315/0001493152-25-019315-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1878313/000149315225019315/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:22:21.715504+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}